“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Kazia Therapeutics
Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.
Kazia Therapeutics — 9 videos in collection
In this video, Kazia’s CEO, Dr James Garner, explains the background to this interesting product which has a novel brain penetrating action which potentially could give it a unique role in the chronic treatment of glioblastoma. He discusses the latest trial data and the further development of the product in 2020.
Get access to the very latest content matched to your personal investment style.
